Latest Administration News

AJ Lucas Group Limited has swung to a $38.9 million half-year profit, buoyed by a significant UK settlement and improved Australian drilling operations despite revenue pressures.

FlexiRoam Limited has reported a remarkable turnaround with a net profit of AUD 1.42 million for the half-year ended 31 December 2025, driven by a shift to high-margin recurring revenue and cost discipline. The launch of its AI-powered eSIM agent and key partnerships underpin this transformation.

Memphasys Limited has advanced its Felix™ System commercial rollout with key regulatory approvals and new international contracts, while trimming operating costs and narrowing losses in the first half of FY2026.

Lumos Diagnostics reported a 74% increase in its half-year loss to US$4.88 million, despite strong progress with its FebriDx diagnostic test and a landmark US distribution agreement. The company awaits a critical FDA decision that could unlock significant revenue growth.

GLG Corp Ltd reported an 18.7% drop in revenue to USD 54.1 million for the half year ended December 2025, resulting in a net loss amid challenging macroeconomic conditions and tariff pressures. Despite operational efficiencies improving gross margins, the company refrained from declaring an interim dividend.

Anteris Technologies Global Corp. posted a $94.2 million loss for 2025 amid a 29% revenue decline, while progressing its pivotal DurAVR THV clinical trial and securing $320 million in early 2026 financings.

Entropy Neurodynamics reports a 14.8% reduction in half-year losses while progressing a pioneering clinical trial for Binge Eating Disorder using its proprietary psychedelic drug TRP-8803. The company also secured $6.1 million in new funding and strategic collaborations to enhance its neuropsychiatry platform.

Strata Investment Holdings plc reported a striking £6.16 million comprehensive profit for 2025, propelled by robust investment portfolio returns and a significant revaluation uplift in its copper royalty assets. Despite operational delays from adverse weather, the company’s strategic focus on high-conviction resource investments and royalties positions it well amid evolving commodity markets.

Mesoblast Limited reported its first commercial sales of FDA-approved Ryoncil, generating $48.7 million in net product sales for the half-year ended December 31, 2025, while reducing its net loss by 16%. The company also secured a $125 million five-year credit facility, restructuring its debt to support ongoing commercialization and development.

NobleOak Life Limited reported a robust half-year performance with underlying net profit after tax rising 11% to $9.6 million, driven by strong premium growth and market share gains. However, statutory profit fell 23% due to one-off costs and provisions, prompting a pause on dividends amid strategic transitions.

ARC Funds Limited posted a $1 million loss for the half-year ending December 2025, while significantly increasing revenues and expanding its ownership in The Term Deposit Shop to 74.48%. The company raised nearly $1.9 million to support growth initiatives amid ongoing operational challenges.

Channel Infrastructure reported steady FY25 financials with record throughput and key project progress, while raising dividends and expanding into Australia via a strategic pipeline stake.